X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The funding will be used for continued development and Investigational New Drug (IND)-enabling studies to support clinical translation of the company's small molecule activators of the SERCA enzyme for Alzheimer's disease.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Small molecule
Recipient: Neurodon
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Funding October 03, 2023
Details:
CT1812 binds selectively to the sigma-2 receptor complex which is involved in the regulation of key cellular processes, that are damaged by toxic interaction with soluble beta amyloid oligomers and currently in development for mild-to-moderate Alzheimer’s disease.
Lead Product(s): CT1812
Therapeutic Area: Neurology Product Name: CT1812
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Cognition Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2023
Details:
OLX-07010 would potentially fill a significant unmet need with a disease-modifying drug that, if successful, will have a tremendous impact on patient outcomes and reduce the burden on caregivers and society.
Lead Product(s): OLX-07010
Therapeutic Area: Neurology Product Name: OLX-07010
Highest Development Status: IND EnablingProduct Type: Small molecule
Recipient: Oligomerix
Deal Size: $3.4 million Upfront Cash: Undisclosed
Deal Type: Funding August 09, 2022
Details:
The grant supports clinical trials of beta-amyloid vaccines based on DNA and recombinant protein for Alzheimer’s disease. A phase 1 clinical study in the U.S. is expected to begin and the vaccine will be delivered by PharmaJet Tropis® Needle-free Injection System.
Lead Product(s): DNA-based Vaccine
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Recipient: Institute for Molecular Medicine
Deal Size: $12.0 million Upfront Cash: Undisclosed
Deal Type: Funding May 24, 2022
Details:
The grant supports clinical trials of beta-amyloid vaccines based on DNA and recombinant protein for Alzheimer’s disease. A phase 1 clinical study in the U.S. is expected to begin and the vaccine will be delivered by PharmaJet Tropis® Needle-free Injection System.
Lead Product(s): Beta-amyloid Vaccine
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Recipient: Institute for Molecular Medicine
Deal Size: $12.0 million Upfront Cash: Undisclosed
Deal Type: Funding May 24, 2022
Details:
NNI-362, at the two multi-doses, 120 mg and 240 mg, was shown to significantly reduce p-tau181 levels versus pre-treatment levels in study participants, also showed a significant reduction of an Alzheimer’s disease pathological biomarker.
Lead Product(s): NNI-362
Therapeutic Area: Neurology Product Name: NNI-362
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Neuronascent
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 30, 2022
Details:
The funding will support the clinical trials of its beta-amyloid (Aβ) vaccines based on DNA (AV-1959D) and recombinant protein (AV-1959R) for the prevention of Alzheimer's disease (AD).
Lead Product(s): AV-1959D
Therapeutic Area: Neurology Product Name: AV-1959D
Highest Development Status: PreclinicalProduct Type: Vaccine
Recipient: The Institute for Molecular Medicine
Deal Size: $12.0 million Upfront Cash: Undisclosed
Deal Type: Funding March 15, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
